BNR (BNR) Stock Price & Analysis
BNR (BNR) fell 9.81% to USD 8.18 as of June 10, 2026 at 03:37 UTC, according to Nexqual real-time market data.
BNR last closed at USD 9.07; the session ranged USD 8.15–8.95 on volume of 33,155 shares. Market capitalization is $86.27M, with a 52-week range of USD 2.95–41.72 (NGM). Source: Nexqual, June 10, 2026 at 03:37 UTC.
Key Statistics (as of June 10, 2026 at 03:37 UTC)
| Price | USD 8.18 |
|---|---|
| Change | ▼ 9.81% (down) |
| Previous Close | USD 9.07 |
| Open | USD 8.95 |
| Day Range | USD 8.15 – 8.95 |
| 52-Week Range | USD 2.95 – 41.72 |
| Volume | 33,155 shares |
| Market Cap | $86.27M |
| Exchange | NGM |
Technical Analysis (BNR)
Nexqual's technical model rates BNR "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 20.3 (oversold) |
| vs SMA50 | Below (USD 15.94) |
| MACD | -2.46 (negative) |
Analyst Ratings (BNR)
Wall Street analysts rate BNR "None", per Nexqual as of June 10, 2026 at 03:37 UTC.
| Consensus Rating | None |
|---|
Earnings (BNR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-03-31 | USD -18.1 vs est -13.9 ▼ miss |
| 2022-12-31 | USD -21.1 vs est -19 ▼ miss |
| 2022-09-30 | USD -23.3 vs est -18.8 ▼ miss |
| 2022-06-30 | USD -25 vs est -18.5 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Financials & Fundamentals (BNR)
| Total Revenue | $539.57M |
|---|---|
| Revenue Growth (YoY) | +0.20% |
| Gross Margin | +74.67% |
| Operating Margin | -9.53% |
| Profit Margin | -10.26% |
| ROE | -9.92% |
| Debt / Equity | 8.06 |
| Current Ratio | 2.99 |
| Total Cash | $480.79M |
| Total Debt | $43.12M |
| Free Cash Flow | $-22.79M |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Financial Health Score (BNR)
Nexqual rates BNR's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:37 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -10% |
| Balance Sheet | Strong — $481M cash vs $43M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$23M, burning cash |
| Efficiency | Critical — ROE -10%, ROA -4.0% |
Ownership (BNR)
| Insider Ownership | +4.01% |
|---|---|
| Institutional Ownership | +46.71% |
| Shares Outstanding | 8.81M |
| Float | 4.07M |
| Short % of Float | +0.50% |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Leadership (BNR)
BNR is led by Yusheng Han (age 46), Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 03:37 UTC.
| Founder, Chairman & CEO | Yusheng Han (age 46) |
|---|---|
| Vice President of Finance | Xiaozhi Hu (age 41) |
| CTO & Director | Zhihong Zhang (age 49) |
Major Backers & Investors (BNR)
Notable institutional backers of BNR include Kynam Capital Management, LP, CRCM LP, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 03:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kynam Capital Management, LP | 13.93% |
| CRCM LP | 3.2% |
| Renaissance Technologies | 0.4% |
| Sumitomo Mitsui Trust Group, Inc. | 0.34% |
| Amova Asset Management Americas Inc | 0.34% |
| Bank of America Corporation | 0.33% |
| HSG Holding Ltd | 0.24% |
| Redwood Wealth Management Group, LLC | 0.21% |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
| NBP | NovaBridge Biosciences | USD 1.59 | ▼ 3.34% |
| NRIX | Nurix Therapeutics, Inc. | USD 15.64 | ▲ 6.83% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.94 | ▲ 3.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:37 UTC. This page is informational and not investment advice.